Kamel IR - Search Results

1

Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Buijs M, et al. Among authors: kamel ir. Cancer. 2013 Mar 1;119(5):1042-9. doi: 10.1002/cncr.27859. Epub 2012 Nov 6. Cancer. 2013. PMID: 23132335 Free PMC article. Clinical Trial.

2

Imaging evaluation of hepatocellular carcinoma.

Kamel IR, Bluemke DA. Kamel IR, et al. J Vasc Interv Radiol. 2002 Sep;13(9 Pt 2):S173-84. doi: 10.1016/s1051-0443(07)61784-9. J Vasc Interv Radiol. 2002. PMID: 12354834 Review.

3

Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma.

Kamel IR, Bluemke DA, Ramsey D, Abusedera M, Torbenson M, Eng J, Szarf G, Geschwind JF. Kamel IR, et al. AJR Am J Roentgenol. 2003 Sep;181(3):708-10. doi: 10.2214/ajr.181.3.1810708. AJR Am J Roentgenol. 2003. PMID: 12933464 No abstract available.

4

Recent advances in CT imaging of liver metastases.

Kamel IR, Fishman EK. Kamel IR, et al. Cancer J. 2004 Mar-Apr;10(2):104-20. doi: 10.1097/00130404-200403000-00006. Cancer J. 2004. PMID: 15130270 Review.

5

Multidetector CT of hepatocellular carcinoma.

Kamel IR, Liapi E, Fishman EK. Kamel IR, et al. Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):63-89. doi: 10.1016/j.bpg.2004.10.005. Best Pract Res Clin Gastroenterol. 2005. PMID: 15757805 Review.

6

Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution.

Burger I, Hong K, Schulick R, Georgiades C, Thuluvath P, Choti M, Kamel I, Geschwind JF. Burger I, et al. J Vasc Interv Radiol. 2005 Mar;16(3):353-61. doi: 10.1097/01.RVI.0000143768.60751.78. J Vasc Interv Radiol. 2005. PMID: 15758131

7

The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.

Kamel IR, Bluemke DA, Eng J, Liapi E, Messersmith W, Reyes DK, Geschwind JF. Kamel IR, et al. J Vasc Interv Radiol. 2006 Mar;17(3):505-12. doi: 10.1097/01.RVI.0000200052.02183.92. J Vasc Interv Radiol. 2006. PMID: 16567675

8

Differences in characteristics of patients with and without known risk factors for hepatocellular carcinoma in the United States.

Dorfman JD, Schulick R, Choti MA, Geschwind JF, Kamel I, Torbenson M, Thuluvath PJ. Dorfman JD, et al. World J Gastroenterol. 2007 Feb 7;13(5):781-4. doi: 10.3748/wjg.v13.i5.781. World J Gastroenterol. 2007. PMID: 17278203 Free PMC article.

9

Functional MR imaging assessment of tumor response after 90Y microsphere treatment in patients with unresectable hepatocellular carcinoma.

Kamel IR, Reyes DK, Liapi E, Bluemke DA, Geschwind JF. Kamel IR, et al. J Vasc Interv Radiol. 2007 Jan;18(1 Pt 1):49-56. doi: 10.1016/j.jvir.2006.10.005. J Vasc Interv Radiol. 2007. PMID: 17296704

10

Assessment of tumor response on MR imaging after locoregional therapy.

Vossen JA, Buijs M, Kamel IR. Vossen JA, et al. Among authors: kamel ir. Tech Vasc Interv Radiol. 2006 Sep;9(3):125-32. doi: 10.1053/j.tvir.2007.02.004. Tech Vasc Interv Radiol. 2006. PMID: 17561215 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

415 results

Search Page

Filters